AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NYRADA INC-CDI

0.485

-0.015-3.00%

Volume:204.73K

Turnover:100.50K

Market Cap:118.64M

PE:-19.31

High:0.500

Open:0.500

Low:0.470

Close:0.500

52wk High:1.435

52wk Low:0.091

Shares:244.62M

Float Shares:102.11M

Volume Ratio:0.49

T/O Rate:0.20%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.025

EPS(LYR):-0.024

ROE:-71.00%

ROA:-41.98%

PB:12.05

PE(LYR):-20.02

Loading ...

Overview Company News Filings

Nyrada On Track To Being Site Initiation Visits For Phase IIa Clinical Trial

MT Newswires Live

Nyrada Discloses Updated Capital Structure

MT Newswires Live

Despite currently being unprofitable, Nyrada (ASX:NYR) has delivered a 776% return to shareholders over 1 year

Simply Wall St.

Nyrada Receives Ethics Committee Nod to Start Drug Candidate Trial for Treatment of Patients With Heart Attack Injuries

MT Newswires Live

Nyrada Insiders May Regret Not Buying More, Market Cap Hits AU$207m

Simply Wall St.

Nyrada Inc.'s (ASX:NYR) stock price dropped 10% last week; individual investors would not be happy

Simply Wall St.

Nyrada Lodges Ethics Submission for Cardioprotection Drug Candidate Phase IIa Clinical Trial, Shares Fall 11%

MT Newswires Live

Nyrada Inc-Nyrada Phase Iia Clinical Trial Update

THOMSON REUTERS

Nyrada (ASX:NYR) shareholder returns have been stellar, earning 185% in 3 years

Simply Wall St.

BRIEF-Nyrada Says James Bonna Appointed As Managing Director

Nyrada Inc - James Bonna Appointed as Managing Director

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NYR.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NYR.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NYR.AU\",,,,,undefined,":{"symbol":"NYR.AU","market":"AU","secType":"STK","nameCN":"NYRADA INC-CDI","latestPrice":0.485,"timestamp":1774329120000,"preClose":0.5,"halted":0,"volume":204729,"delay":0,"changeRate":-0.030000000000000027,"nameEN":"NYRADA INC-CDI","floatShares":102113109,"shares":244616371,"eps":-0.025116,"marketStatus":"Not Yet Opened","change":-0.015,"latestTime":"03-24 16:12:00 AEDT","open":0.5,"high":0.5,"low":0.47,"amount":100498,"amplitude":0.06,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.025116,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1774393200000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.5,"openAndCloseTimeList":[[1774306800000,1774328400000]],"volumeRatio":0.4900897164699791,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"NYR.AU","preClose":0.5,"auctionPrice":0.485,"auctionVolume":3174,"auction":3,"marketStatus":"盘后竞价","timestamp":1774328971058}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NYR.AU\",,,,,undefined,":{"symbol":"NYR.AU","floatShares":102113109,"roa":"-41.98%","roe":"-71.00%","lyrEps":-0.024221,"volumeRatio":0.4900897164699791,"shares":244616371,"dividePrice":0,"high":0.5,"amplitude":0.06,"preClose":0.5,"low":0.47,"week52Low":0.091,"pbRate":"12.05","psRate":"49.87","week52High":1.435,"institutionHeld":0,"latestPrice":0.485,"eps":-0.025116,"divideRate":0,"volume":204729,"delay":0,"ttmEps":-0.025116,"open":0.5,"prevYearClose":1.12,"prevWeekClose":0.5,"prevMonthClose":0.665,"prevQuarterClose":1.12,"fiveDayClose":0.53,"twentyDayClose":0.605,"sixtyDayClose":0.85},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NYR.AU\",params:#limit:5,,,undefined,":[{"date":"2023-07-28","symbol":"NYR.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1690502400000,"name":null,"time":"","dateTimestamp":1690466400000,"actualEps":null},{"date":"2023-04-29","symbol":"NYR.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1682726400000,"name":null,"time":"","dateTimestamp":1682690400000,"actualEps":null},{"market":"AU","date":"2022-08-29","symbol":"NYR.AU","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1661695200000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NYR.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NYR.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2620299589","title":"Nyrada On Track To Being Site Initiation Visits For Phase IIa Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2620299589","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620299589?lang=en_us&edition=fundamental","pubTime":"2026-03-19 08:12","pubTimestamp":1773879136,"startTime":"0","endTime":"0","summary":"Nyrada  said it was on track to begin site initiation visits for its PROTECT-MI Phase IIa trial, which is designed to assess the safety and preliminary efficacy of its drug candidate Xolatryp in addressing myocardial ischemia reperfusion injury in patients suffering a STEMI heart attack, inMarch, according to a Thursday Australian bourse filing.Seven hospitals were selected as initial sites, with the first patient dosing expected in April. The enrolment of patients in the PROTECT-MI study will finish once 100 evaluable patients are dosed.Its shares fell 2% in recent trading on Thursday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NYR.AU","BK7096"],"gpt_icon":0},{"id":"2612413149","title":"Nyrada Discloses Updated Capital Structure","url":"https://stock-news.laohu8.com/highlight/detail?id=2612413149","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612413149?lang=en_us&edition=fundamental","pubTime":"2026-02-18 14:05","pubTimestamp":1771394738,"startTime":"0","endTime":"0","summary":"Nyrada (ASX:NYR) reported 244.9 million CHESS depositary interests, 21.3 million vested options, and 31.4 million unvested options as at Feb. 12, according to a Wednesday Australian bourse filing.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NYR.AU","XAO.AU","BK7096","XJO.AU","XKO.AU"],"gpt_icon":0},{"id":"2609469855","title":"Despite currently being unprofitable, Nyrada (ASX:NYR) has delivered a 776% return to shareholders over 1 year","url":"https://stock-news.laohu8.com/highlight/detail?id=2609469855","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609469855?lang=en_us&edition=fundamental","pubTime":"2026-02-07 04:41","pubTimestamp":1770410493,"startTime":"0","endTime":"0","summary":"Nyrada Inc. ( ASX:NYR ) shareholders might be rather concerned because the share price has dropped 46% in the last...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-nyr/nyrada-shares/news/despite-currently-being-unprofitable-nyrada-asxnyr-has-deliv","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-nyr/nyrada-shares/news/despite-currently-being-unprofitable-nyrada-asxnyr-has-deliv","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NYR.AU","BK7096"],"gpt_icon":0},{"id":"2601331403","title":"Nyrada Receives Ethics Committee Nod to Start Drug Candidate Trial for Treatment of Patients With Heart Attack Injuries","url":"https://stock-news.laohu8.com/highlight/detail?id=2601331403","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601331403?lang=en_us&edition=fundamental","pubTime":"2026-01-08 09:25","pubTimestamp":1767835551,"startTime":"0","endTime":"0","summary":"Nyrada  received approval from the Human Research Ethics Committee to start the Phase IIa clinical randomised, double-blind, placebo-controlled, multicenter trial of its small-molecule inhibitor Xolatryp in the treatment of myocardial ischemia reperfusion injury in patients suffering a heart attack, according to a Thursday filing with the Australian bourse.The trial will evaluate the safety and preliminary efficacy of Xolatryp in treating the injury in about 200 patients, the filing said.It will also evaluate multiple secondary efficacy signals, including cardiac function and extent of cardiac injury, the filing added.The company expects to start patient recruitment and dosing in March for the trial, the filing added.It expects to complete the trial within 18 months after the patient is dosed.Shares of the company rose 2% in recent Thursday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NYR.AU","BK7096"],"gpt_icon":0},{"id":"2594287207","title":"Nyrada Insiders May Regret Not Buying More, Market Cap Hits AU$207m","url":"https://stock-news.laohu8.com/highlight/detail?id=2594287207","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2594287207?lang=en_us&edition=fundamental","pubTime":"2025-12-25 11:34","pubTimestamp":1766633662,"startTime":"0","endTime":"0","summary":"Last week, Nyrada Inc. ( ASX:NYR ) insiders, who had purchased shares in the previous 12 months were rewarded...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-nyr/nyrada-shares/news/nyrada-insiders-may-regret-not-buying-more-market-cap-hits-a","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-nyr/nyrada-shares/news/nyrada-insiders-may-regret-not-buying-more-market-cap-hits-a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NYR.AU","BK7096"],"gpt_icon":0},{"id":"2584901886","title":"Nyrada Inc.'s (ASX:NYR) stock price dropped 10% last week; individual investors would not be happy","url":"https://stock-news.laohu8.com/highlight/detail?id=2584901886","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584901886?lang=en_us&edition=fundamental","pubTime":"2025-11-20 08:48","pubTimestamp":1763599721,"startTime":"0","endTime":"0","summary":"Key Insights Nyrada's significant individual investors ownership suggests that the key decisions are influenced by...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-nyr/nyrada-shares/news/nyrada-incs-asxnyr-stock-price-dropped-10-last-week-individu","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-nyr/nyrada-shares/news/nyrada-incs-asxnyr-stock-price-dropped-10-last-week-individu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7096","NYR.AU"],"gpt_icon":0},{"id":"2584602126","title":"Nyrada Lodges Ethics Submission for Cardioprotection Drug Candidate Phase IIa Clinical Trial, Shares Fall 11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584602126","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584602126?lang=en_us&edition=fundamental","pubTime":"2025-11-18 11:15","pubTimestamp":1763435724,"startTime":"0","endTime":"0","summary":"Nyrada  said it submitted a human research ethics committee application for its phase IIa clinical trial of its Xolatryp drug candidate in patients with ST-elevation myocardial infarction undergoing a percutaneous coronary intervention treatment, according to a Tuesday Australian bourse filing.The percutaneous coronary intervention treatment is associated with myocardial ischemia reperfusion injury that occurs when blood flow is restored to the heart after the ST-elevation myocardial infarction, a severe form of a heart attack.The randomized, double-blind, placebo-controlled, multicenter study aims to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Xolatryp in male and female patients with ST-elevated myocardial infarction who are undergoing primary percutaneous coronary intervention. Around 200 patients are expected to be dosed during the trial.The trial is on track to commence with patient dosing in March 2026, and the committee's fina","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NYR.AU","BK7096"],"gpt_icon":0},{"id":"2584082576","title":"Nyrada Inc-Nyrada Phase Iia Clinical Trial Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2584082576","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584082576?lang=en_us&edition=fundamental","pubTime":"2025-11-18 07:54","pubTimestamp":1763423699,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nTUE7LTZJK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NYR.AU","BK7096"],"gpt_icon":0},{"id":"2575984817","title":"Nyrada (ASX:NYR) shareholder returns have been stellar, earning 185% in 3 years","url":"https://stock-news.laohu8.com/highlight/detail?id=2575984817","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575984817?lang=en_us&edition=fundamental","pubTime":"2025-10-16 06:52","pubTimestamp":1760568770,"startTime":"0","endTime":"0","summary":"The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-nyr/nyrada-shares/news/nyrada-asxnyr-shareholder-returns-have-been-stellar-earning","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-nyr/nyrada-shares/news/nyrada-asxnyr-shareholder-returns-have-been-stellar-earning","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NYR.AU","BK7096"],"gpt_icon":0},{"id":"2573691816","title":"BRIEF-Nyrada Says James Bonna Appointed As Managing Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2573691816","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573691816?lang=en_us&edition=fundamental","pubTime":"2025-10-08 09:35","pubTimestamp":1759887358,"startTime":"0","endTime":"0","summary":"BRIEF-Nyrada Says James Bonna Appointed As Managing DirectorOct 8 (Reuters) - Nyrada Inc NYR.AX:JAMES BONNA APPOINTED AS MANAGING DIRECTORFurther company coverage: NYR.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251008:nFWN3VO2PS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NYR.AU","BK7096"],"gpt_icon":0},{"id":"2573991759","title":"Nyrada Inc -  James Bonna Appointed as Managing Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2573991759","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573991759?lang=en_us&edition=fundamental","pubTime":"2025-10-08 06:41","pubTimestamp":1759876909,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251007:nFWN3VO2PS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","NYR.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":11,"code":"91000000","status":"200"}]}}